uniQure N.V. Employee-related Liabilities, Current
uniQure N.V. (QURE) had Employee-related Liabilities, Current of $10.13 million as of 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:EmployeeRelatedLiabilitiesCurrent · last filed 2026-05-05
- 2026-03-31: Employee-related Liabilities, Current $10.13M.
- 2025-12-31: Employee-related Liabilities, Current $9.94M.
- 2025-09-30: Employee-related Liabilities, Current $26.53M.
- 2025-06-30: Employee-related Liabilities, Current $8.29M.
| Period end | Employee-related Liabilities, Current | Employee-related Liabilities, Current as first filed |
|---|---|---|
| 2026-03-31 | $10.13M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $9.94M 10-Q · filed 2026-05-05 | |
| 2025-09-30 | $26.53M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $8.29M 10-Q · filed 2025-07-29 | |
| 2025-03-31 | $10.92M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $12.29M 10-K · filed 2026-03-02 | $12.58M 10-K · filed 2025-02-27 |
| 2024-09-30 | $15.44M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $11.02M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $9.57M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $16.26M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $16.24M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $12.31M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $9.35M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $17.20M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $12.94M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $7.85M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $9.60M 10-Q · filed 2022-05-02 | |
| 2021-12-31 | $12.60M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $10.90M 10-Q · filed 2021-10-25 | |
| 2021-06-30 | $6.79M 10-Q · filed 2021-07-26 | |
| 2021-03-31 | $4.72M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $7.69M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $8.58M 10-Q · filed 2020-10-27 | |
| 2020-06-30 | $6.62M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $3.53M 10-Q · filed 2020-04-29 | |
| 2019-12-31 | $7.03M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $6.53M 10-Q · filed 2019-10-28 | |
| 2019-06-30 | $4.43M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $4.35M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $5.69M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $3.86M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $4.69M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $2.25M 10-Q · filed 2018-04-30 | |
| 2017-12-31 | $5.65M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $4.48M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $3.97M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $2.25M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $5.56M 10-K · filed 2018-03-14 | $4.38M 10-K · filed 2017-03-15 |
| 2015-12-31 | $3.25M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |